Judith K Grether
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Judith K Grether has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Angelina Kakooza-Mwesige
Makerere University-Mulago National Referral Hospital, Uganda
1 shared publication- Cathleen Yoshida
Kaiser Permanente Northern California Division of Research 2000 Broadway, Oakland, CA 94612, United States
1 shared publication Charles Karamagi
Makerere University—Mulago National Referral Hospital, Uganda
1 shared publicationDaniel Smith
Sequoia Foundation, USA Kaiser Permanente Division of Research, USA
1 shared publication- Edwin Trevathan
Departments of Pediatrics and Neurology, Vanderbilt Institute for Global Health, Vanderbilt University School of Medicine, Nashville, TN
1 shared publication - Gerald N. DeLorenze
Division of Research, Kaiser Permanente Northern California, Oakland
1 shared publication
Latest Publications
- Open Access
- 1 January 2014
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 11 (1) , 113
Neonatal cytokines and chemokines and risk of Autism Spectrum Disorder: the Early Markers for Autism (EMA) study: a case-control study
Biologic markers of infection and inflammation have been associated with Autism Spectrum Disorders (ASD) but prior studies have largely relied on specimens taken after clinical diagnosis. Research on potential biologic markers early in neurodevelopment is required to evaluate possible causal pathways and screening profiles.
- 1 January 2014
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 11 (1) , 113
Open AccessNeonatal cytokines and chemokines and risk of Autism Spectrum Disorder: the Early Markers for Autism (EMA) study: a case-control study
Biologic markers of infection and inflammation have been associated with Autism Spectrum Disorders (ASD) but prior studies have largely relied on specimens taken after clinical diagnosis. Research on potential biologic markers early in neurodevelopment is required to evaluate possible causal pathways and screening profiles.
- Open Access
- 27 March 2013
- Published by SAGE Publications in Autism
- Vol. 18 (4) , 447-457
Adaptation of the “ten questions” to screen for autism and other neurodevelopmental disorders in Uganda
Neurodevelopmental disorders are recognized to be relatively common in developing countries but little data exist for planning effective prevention and intervention strategies. In particular, data on autism spectrum disorders are lacking. For application in Uganda, we developed a 23-question screener (23Q) that includes the Ten Questions screener and additional questions on autism spectrum disorder behaviors. We then conducted household screening of 1169 children, 2–9 years of age, followed by clinical assessment of children who screened positive and a sample of those who screened negative to evaluate the validity of the screener. We found that 320 children (27% of the total) screened positive and 68 children received a clinical diagnosis of one or more moderate to severe neurodevelopmental disorders (autism spectrum disorder; cerebral palsy; epilepsy; cognitive, speech and language, hearing, or vision impairment), including 8 children with autism spectrum disorders. Prevalence and validity of the screener were evaluated under different statistical assumptions. Sensitivity of the 23Q ranged from 0.55 to 0.80 and prevalence for ≥1 neurodevelopmental disorders from 7.7/100 children to 12.8/100 children depending on which assumptions were used. The combination of screening positive on both autism spectrum disorders and Ten Questions items was modestly successful in identifying a subgroup of children at especially high risk of autism spectrum disorders. We recommend that autism spectrum disorders and related behavioral disorders be included in studies of neurodevelopmental disorders in low-resource settings to obtain essential data for planning local and global public health responses.
- 27 March 2013
- Published by SAGE Publications in Autism
- Vol. 18 (4) , 447-457
Open AccessAdaptation of the “ten questions” to screen for autism and other neurodevelopmental disorders in Uganda
Neurodevelopmental disorders are recognized to be relatively common in developing countries but little data exist for planning effective prevention and intervention strategies. In particular, data on autism spectrum disorders are lacking. For application in Uganda, we developed a 23-question screener (23Q) that includes the Ten Questions screener and additional questions on autism spectrum disorder behaviors. We then conducted household screening of 1169 children, 2–9 years of age, followed by clinical assessment of children who screened positive and a sample of those who screened negative to evaluate the validity of the screener. We found that 320 children (27% of the total) screened positive and 68 children received a clinical diagnosis of one or more moderate to severe neurodevelopmental disorders (autism spectrum disorder; cerebral palsy; epilepsy; cognitive, speech and language, hearing, or vision impairment), including 8 children with autism spectrum disorders. Prevalence and validity of the screener were evaluated under different statistical assumptions. Sensitivity of the 23Q ranged from 0.55 to 0.80 and prevalence for ≥1 neurodevelopmental disorders from 7.7/100 children to 12.8/100 children depending on which assumptions were used. The combination of screening positive on both autism spectrum disorders and Ten Questions items was modestly successful in identifying a subgroup of children at especially high risk of autism spectrum disorders. We recommend that autism spectrum disorders and related behavioral disorders be included in studies of neurodevelopmental disorders in low-resource settings to obtain essential data for planning local and global public health responses.